scholarly journals Effect of vitamin D supplementation on serum 25-hydroxyvitamin D concentration in children and adolescents: a systematic review and meta-analysis protocol

BMJ Open ◽  
2018 ◽  
Vol 8 (9) ◽  
pp. e021636 ◽  
Author(s):  
Golaleh Asghari ◽  
Hossein Farhadnejad ◽  
Farhad Hosseinpanah ◽  
Nazanin Moslehi ◽  
Parvin Mirmiran ◽  
...  
Keyword(s):  
Vitamin D ◽  
Children And Adolescents ◽  
Vitamin D Supplementation ◽  
Control Group ◽  
Placebo Control ◽  
Controlled Trials ◽  
Cochrane Central Register ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D ◽  
The Impact

IntroductionThe importance of vitamin D for bone health as well as its role in non-skeletal functions has long been documented. However, review investigations on the effect of vitamin D supplementation on serum 25-hydroxyvitamin D (25(OH)D) levels in children and adolescents are scarce. The aims of the current study were to assess the impact of various doses of vitamin D supplementation on serum 25(OH)D concentrations in children and adolescents, and to identify relevant determinants of variations in the effect of vitamin D supplementation.MethodsPubMed, Scopus, ISI Web of Science and Cochrane Central Register of Controlled Trials databases up to 27 September 2017 will systematically be searched for randomised controlled trials of vitamin D supplementation. We considered articles with the following control groups as eligible: placebo control, control group without any supplementation or a comparative arm investigation. Two reviewers will assess articles for eligibility according to prespecified selection criteria, after which data extraction and quality appraisal will be conducted by two independent reviewers. The quality assessment will be assessed using the Jadad scale. Meta-analyses will be conducted where appropriate. We will express continuous measures (ie, serum 25(OH)D concentration) as mean differences with 95% CIs. Heterogeneity of the data will be investigated via visual inspection of the forest plots and using χ2test on N-1 df, with a significance level of α=0.1. We will also assess individual study and subgroup characteristics and perform a sensitivity analysis. Publication bias will be assessed using funnel plot and statistical analysis of Egger’s test.Ethics and disseminationEthics approval is not required because the work will be carried out on published documents. The authors will publish findings from this review through peer-reviewed publication or conference presentations.PROSPERO registration numberCRD42017067179.

scholarly journals Is the Climb Worth the View? The Savings/Alert Ratio for Reducing Vitamin D Testing

2020 ◽  
Vol 11 (01) ◽  
pp. 160-165
Author(s):  
Chase D. Hendrickson ◽  
Michael F. McLemore ◽  
Kathryn M. Dahir ◽  
Shari Just ◽  
Zahra Shajani-Yi ◽  
...  
Keyword(s):  
Vitamin D ◽  
Medical Center ◽  
Intervention Group ◽  
Clinical Decision ◽  
Control Group ◽  
Hydroxyvitamin D ◽  
Patient Demographics ◽  
25 Hydroxyvitamin D ◽  
A Charge ◽  
The Impact

Abstract Background Despite guideline recommendations, vitamin D testing has increased substantially. Clinical decision support (CDS) presents an opportunity to reduce inappropriate laboratory testing. Objectives and Methods To reduce inappropriate testing of vitamin D at the Vanderbilt University Medical Center, a CDS assigned providers to receive or not receive an electronic alert each time a 25-hydroxyvitamin D assay was ordered for an adult patient unless the order was associated with a diagnosis in the patient's chart for which vitamin D testing is recommended. The CDS ran for 80 days, collecting data on number of tests, provider information, and basic patient demographics. Results During the 80 days, providers placed 12,368 orders for 25-hydroxyvitamin D. The intervention group ordered a vitamin D assay and received the alert for potentially inappropriate testing 2,181 times and completed the 25-hydroxyvitamin D order in 89.9% of encounters, while the control group ordered a vitamin D assay (without receiving an alert) 2,032 times and completed the order in 98.1% of encounters, for an absolute reduction of testing of 8% (p < 0.001). Conclusion This CDS reduced vitamin D ordering by utilizing a soft-stop approach. At a charge of $179.00 per test and a cost to the laboratory of $4.20 per test, each display of the alert led to an average reduction of $14.70 in charges and of $0.34 in spending by the laboratory (the savings/alert ratio). By describing the effectiveness of an electronic alert in terms of the savings/alert ratio, the impact of this intervention can be better appreciated and compared with other interventions.

scholarly journals Impact of vitamin D supplementation on health-care use in a 25-hydroxyvitamin D-tested population in France: a population-based descriptive cohort study

2014 ◽  
Vol 18 (3) ◽  
pp. 554-561 ◽  
Author(s):  
Pascal Caillet ◽  
Susan B Jaglal ◽  
Laurent Laforest ◽  
Roland Chapurlat ◽  
Muriel Rabilloud ◽  
...  
Keyword(s):  
Health Care ◽  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Muscle Relaxant ◽  
Vitamin D Supplementation ◽  
Insurance Fund ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D ◽  
The Impact ◽  
Health Care Claims

AbstractObjectiveChronic vitamin D deficiency has been associated in some patients with diffuse musculoskeletal pain. These unspecific symptoms may partly explain why vitamin D deficiency is often diagnosed late. Our aim was to analyse health-care claims after vitamin D supplementation in patients likely to have vitamin D deficiency.DesignAmbulatory health-care claims were compared before and after a vitamin D supplementation prescribed following a 25-hydroxyvitamin D assay.SettingHealth Insurance Fund (FHIF) database of the Rhône-Alpes area, France.SubjectsAmong patients reimbursed for a 25-hydroxyvitamin D assay between 1 December 2008 and 31 January 2009, those supplemented with vitamin D after the assay were matched on the date of assay to patients who did not receive vitamin D.ResultsAmong the 3023 patients who had a 25-hydroxyvitamin D assay, 935 were consequently supplemented and matched to 935 patients not supplemented. Their median age was 50·0 and 49·5 years, respectively. Patients supplemented decreased their muscle relaxant consumption whereas no change was observed in the reference group, the difference between the two groups was significant (P=0·03). Second and third Pain Relief Ladder prescriptions decreased in both groups but not significantly differently between groups (P=0·58). There was a decrease in prescriptions of biological examination in both groups with no significant difference.ConclusionsBesides a decrease in muscle relaxant prescriptions in the supplemented group, it was difficult to assess the impact of vitamin D supplementation in patients likely to have vitamin D deficiency. Prospective cohort studies and randomized trials are needed to assess the efficiency of screening and supplementing vitamin D deficiency.

scholarly journals The Impact of Vitamin D on Weight Loss

2013 ◽  
Vol 09 (02) ◽  
pp. 146
Author(s):  
Rebecca L Thomson ◽  
Keyword(s):  
Vitamin D ◽  
Weight Loss ◽  
Vitamin D Supplementation ◽  
Hydroxyvitamin D ◽  
Vitamin D Intake ◽  
Before And After ◽  
25 Hydroxyvitamin D ◽  
Weight Loss Interventions ◽  
The Impact ◽  
Weight Loss Success

The incidence of vitamin D deficiency is increasing and 25-hydroxyvitamin D (25OHD) levels, which are inversely associated with measures of obesity, are lower in overweight and obese populations. There have been several studies that have investigated the effect of vitamin D supplementation on weight loss, and studies combining weight loss interventions with increased vitamin D intake, either through supplementation or foods fortified with vitamin D. 25OHD levels have also been measured before and after weight loss to see if they improve and if the changes in 25OHD levels are related to the degree of weight loss. Some studies have suggested that vitamin D status is associated with weight loss success, with supplementation resulting in weight loss, or higher baseline 25OHD or greater increases in 25OHD levels associated with greater weight loss, although this has not been shown in all studies.

The impact of sun protective behavior and vitamin D supplementation on vitamin D level in melanoma patients.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e19025-e19025
Author(s):  
Rachit Kumar ◽  
Sarika Khanna ◽  
Patricia Reutemann ◽  
Kurt S Wenk ◽  
Suraj S. Venna ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D Supplementation ◽  
Protective Behavior ◽  
Protective Behaviors ◽  
Chi Square ◽  
Hydroxyvitamin D ◽  
Chi Square Test ◽  
25 Hydroxyvitamin D ◽  
Melanoma Patients ◽  
The Impact

e19025 Background: Vitamin D (VitD) is synthesized in the skin as a result of exposure to sunlight and its deficiency is common in the general population as well as in cancer patients. Sun protection is strongly recommended for patients after a melanoma diagnosis. We conducted a pilot study to assess the prevalence of VitD deficiency and the impact of both sun protective behavior and VitD supplementation on VitD levels in melanoma patients Methods: Adult patients with AJCC Stage 0-III melanoma were recruited from the Washington Cancer Institute between July 2011 and January 2012. Subjects completed a questionnaire asking about oral VitD supplementation and sun protective behaviors. VitD deficiency was defined by a 25-hydroxyvitamin D (25(OH)D) level less than 30ng/mL. Pearson Chi-square test and multivariate logistic regression were used to determine predictors of VitD deficiency. Results: A total of 49 participants (20 males, 29 females) completed the questionnaire and provided a blood sample for 25(OH)D determinations. Median age was 52 years (23-82), and most (n=48, 98%) were Caucasian. The majority had either stage 0 (n= 13, 27%) or 1 (n=29, 59%) melanoma. Twenty-six (53%) reported regular use of VitD supplements, and the majority reported sun protective behaviors (n=36, 73%). The prevalence of VitD deficiency was 46% (n=23). VitD deficiency was more common in patients who were not taking VitD supplementation (73% vs. 26%, p<0.01). Other associations include: (1) BMI>25 vs. BMI ≤25 (57% vs. 33%, p=0.10); (2) winter vs. summer months(54% vs. 40%, p=0.34); (3) those who practiced sun protective behavior vs. not (50% vs. 38%, p=0.48). On multivariate analysis, the use or non-use of VitD supplementation remained the only significant predictor of VitD deficiency (OR=0.11, p<0.01). Conclusions: VitD deficiency is common in melanoma patients especially in those who are not on VitD supplementation.

scholarly journals 25-Hydroxyvitamin D Concentrations Are Lower in Patients with Positive PCR for SARS-CoV-2

Nutrients ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 1359 ◽  
Author(s):  
Antonio D’Avolio ◽  
Valeria Avataneo ◽  
Alessandra Manca ◽  
Jessica Cusato ◽  
Amedeo De Nicolò ◽  
...  
Keyword(s):  
Vitamin D ◽  
Population Studies ◽  
Large Population ◽  
Vitamin D Supplementation ◽  
Preliminary Observation ◽  
Controlled Trials ◽  
Risk Of Infection ◽  
Hydroxyvitamin D ◽  
Randomized Controlled ◽  
25 Hydroxyvitamin D

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), with a clinical outcome ranging from mild to severe, including death. To date, it is unclear why some patients develop severe symptoms. Many authors have suggested the involvement of vitamin D in reducing the risk of infections; thus, we retrospectively investigated the 25-hydroxyvitamin D (25(OH)D) concentrations in plasma obtained from a cohort of patients from Switzerland. In this cohort, significantly lower 25(OH)D levels (p = 0.004) were found in PCR-positive for SARS-CoV-2 (median value 11.1 ng/mL) patients compared with negative patients (24.6 ng/mL); this was also confirmed by stratifying patients according to age >70 years. On the basis of this preliminary observation, vitamin D supplementation might be a useful measure to reduce the risk of infection. Randomized controlled trials and large population studies should be conducted to evaluate these recommendations and to confirm our preliminary observation.

scholarly journals Vitamin D to prevent exacerbations of COPD: systematic review and meta-analysis of individual participant data from randomised controlled trials

Thorax ◽  
2019 ◽  
Vol 74 (4) ◽  
pp. 337-345 ◽  
Author(s):  
David A Jolliffe ◽  
Lauren Greenberg ◽  
Richard L Hooper ◽  
Carolien Mathyssen ◽  
Rachida Rafiq ◽  
...  
Keyword(s):  
Vitamin D ◽  
Meta Analysis ◽  
Vitamin D Supplementation ◽  
Controlled Trials ◽  
Individual Participant Data ◽  
Hydroxyvitamin D ◽  
Copd Exacerbations ◽  
Individual Participant ◽  
25 Hydroxyvitamin D ◽  
Randomised Controlled

BackgroundRandomised controlled trials (RCTs) of vitamin D to prevent COPD exacerbations have yielded conflicting results.Individual participant data meta-analysis could identify factors that explain this variation.MethodsPubMed, Embase, the Cochrane Central Register of Controlled Trials and Web of Science were searched from inception up to and including 5 October 2017 to identify RCTs of vitamin D supplementation in patients with COPD that reported incidence of acute exacerbations. Individual participant data meta-analysis was performed using fixed effects models adjusting for age, sex, Global Initiative for Chronic Obstructive Lung Disease spirometric grade and trial.ResultsFour eligible RCTs (total 560 participants) were identified; individual participant data were obtained for 469/472 (99.4%) participants in three RCTs. Supplementation did not influence overall rate of moderate/severe COPD exacerbations (adjusted incidence rate ratio (aIRR) 0.94, 95% CI 0.78 to 1.13). Prespecified subgroup analysis revealed that protective effects were seen in participants with baseline 25-hydroxyvitamin D levels <25 nmol/L (aIRR 0.55, 95% CI 0.36 to 0.84) but not in those with baseline 25-hydroxyvitamin D levels ≥25 nmol/L (aIRR 1.04, 95% CI 0.85 to 1.27; p for interaction=0.015). Vitamin D did not influence the proportion of participants experiencing at least one serious adverse event (adjusted OR 1.16, 95% CI 0.76 to 1.75).ConclusionsVitamin D supplementation safely and substantially reduced the rate of moderate/severe COPD exacerbations in patients with baseline 25-hydroxyvitamin D levels <25 nmol/L but not in those with higher levels.Trial registration numberCRD42014013953.

Sign in / Sign up

Export Citation Format

Share Document